CellPoint app analytics for January 14

The CellPoint application has been developed for oncology patients enrolled in CellPoint CAR-T therapies at the point-of-care. The CellPoint application can be linked to the CardioWatch 287-2B bracelet. This bracelet and the application are intended for continuous monitoring of vital signs and capturing questionnaires throughout the patient’s treatment with CAR-T therapies. The CardioWatch 287-2B is a medically certified wireless remote monitoring system intended for continuous collection of vital parameters in home and in healthcare settings. CardioWatch 287 is a CE medical device certified under EU-MDR standards.  Data is transmitted wirelessly from the device via the application to the health cloud where it is stored and made available for further analysis. About CellPoint CellPoint, a Galapagos company, is dedicated to developing CAR-T therapies at the point-of-care, making these therapies more affordable and accessible to patients. CellPoint has developed a rapid manufacturing process, powered by its proprietary xCellit real-time monitoring software system, that allows for 1 week vein-to-vein time compared to over one month with current industry manufacturing platforms. A first proprietary CD19 CAR-T investigational therapy is currently in Phase1/2a trials to provide fast clinical validation of the decentralized point-of-care production model. More information at www.cellpoint.bio.  This application is only supported by phones with Bluetooth® 5.0 Low Energy. For Non European customers, CardioWatch 287 is available as Investigative device to collect body metrics data.  The device is not used for medical diagnostic or treatment. No physical harm risk.